. Author manuscript; available in PMC: 2021 Nov 10.

Published in final edited form as: Infect Control Hosp Epidemiol. 2016 Mar 30;37(7):768–776. doi: 10.1017/ice.2016.60

Table 3.

Clinical outcomes stratified by comparison group.

	No. (%)			OR (95% CI) P value
Outcome	Control	Non-ESBL	ESBL	Non-ESBL vs. Control	ESBL vs. Control	ESBL vs. Non-ESBL
30-day mortality	27 (5.5)	11 (2.2)	11 (2.2)	0.36 (0.17-0.77) p=0.009	0.41 (0.20-0.82) p=0.01	1.00 (0.42-2.40) p=1.00
1-year mortality	72 (14.6)	46 (9.3)	56 (11.4)	0.58 (0.39-0.88) p=0.009	0.74 (0.50-1.08) p=0.12	1.26 (0.83-1.93) p=0.28
Post-culture LOS, days, median (range)^a	--	11 (0-419)	22 (0-985)	--	--	p=0.001
90-day hospital readmission^a	28 (5.7)	50 (10.2)	66 (13.4)	2.00 (1.20-3.34) p=0.008	3.38 (1.93-5.90) p<0.001	1.44 (0.94-2.21) p=0.09

OR, odds ratio; CI, confidence interval; ESBL, extended-spectrum beta-lactamase; LOS, length of stay

For inpatients only